This brand name is authorized in Australia, South Africa, Spain.
The drug CELLUFRESH contains one active pharmaceutical ingredient (API):
1
|
UNII
K679OBS311 - CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED
|
|
Carmellose sodium has no pharmacological effect. Carmellose sodium has a high viscosity resulting in an increased retention time on the eye. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| S01XA20 | Artificial tears and other indifferent preparations | S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 2338C, 5506T |
| ES | Centro de información online de medicamentos de la AEMPS | 61009 |
| ZA | Health Products Regulatory Authority | 32/15.4/0477 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.